Gonadorelin for HPT Axis Support

Candidate profile

Men on testosterone replacement therapy (TRT) or anabolic protocols who want to maintain testicular function, intratesticular testosterone production, and fertility potential. Also relevant for men with hypogonadotropic hypogonadism who need pituitary-gonadal axis stimulation without exogenous testosterone.

Gonadorelin is a bioidentical GnRH (gonadotropin-releasing hormone) analog. It works through the physiological pathway — stimulating the pituitary to release LH and FSH — rather than bypassing it (as hCG does). This makes it mechanistically preferable for long-term axis maintenance.

Approach

Subcutaneous injection of gonadorelin to provide pulsatile GnRH receptor stimulation, maintaining pituitary gonadotropin secretion (LH and FSH) that exogenous testosterone suppresses. During TRT, the hypothalamus stops producing GnRH because testosterone levels are already elevated. Without GnRH, LH and FSH drop to near zero, causing testicular atrophy, cessation of spermatogenesis, and loss of intratesticular testosterone production. Gonadorelin replaces the suppressed hypothalamic signal.

Protocol design

Primary peptide: Gonadorelin, 100–200 mcg per injection

Route: Subcutaneous injection

Frequency: 2× per week (e.g., Monday/Thursday)

Timing: Morning, to approximate physiological GnRH pulsatility

Duration: Ongoing, concurrent with TRT or suppressive protocol

Dosing rationale: The 100–200 mcg range is based on practitioner protocols and pharmacokinetic modeling. Higher doses risk pituitary desensitization — continuous GnRH exposure (as opposed to pulsatile) paradoxically suppresses gonadotropins (this is the mechanism of GnRH agonist drugs like leuprolide used in prostate cancer).

Why not hCG? hCG directly stimulates Leydig cells via the LH receptor but does not maintain FSH secretion. Gonadorelin stimulates both LH and FSH release from the pituitary, preserving spermatogenesis more completely. Additionally, FDA reclassification of compounded hCG has reduced availability in some jurisdictions, making gonadorelin the practical alternative.

Timeline & milestones

Weeks 1–4: LH and FSH levels should become detectable (they are typically suppressed to <0.5 mIU/mL on TRT). Testicular volume stabilization begins.

Weeks 4–12: Measurable LH and FSH levels confirm pituitary responsiveness. Intratesticular testosterone production is maintained (though systemic testosterone levels are dominated by exogenous TRT).

Months 3–6: Testicular volume should be maintained or partially restored (versus progressive atrophy without intervention). Semen analysis, if performed, should show maintained spermatogenesis.

Ongoing: Continued concurrent use with TRT. Unlike hCG, gonadorelin does not produce tachyphylaxis at appropriate pulsatile dosing.

Monitoring

• LH and FSH: Baseline (pre-gonadorelin, on TRT) and every 3 months — confirms pituitary response to GnRH stimulation
• Testicular volume: Baseline and every 6 months (ultrasound or orchidometer) — the physical endpoint that matters
• Semen analysis: If fertility preservation is the goal, baseline and every 6 months
• Total and free testosterone: Every 3 months — gonadorelin should not significantly alter systemic testosterone levels when added to stable TRT
• Estradiol: Monitor as part of TRT management — gonadorelin-maintained intratesticular testosterone adds to the aromatizable androgen pool

When to adjust

• LH/FSH remain undetectable at week 8: Increase dose to 200 mcg 2× per week. If still undetectable at week 12, pituitary responsiveness may be permanently impaired (prolonged suppression can cause gonadotroph atrophy).
• Testicular atrophy progresses despite treatment: Add hCG as a direct Leydig cell stimulus while continuing gonadorelin for FSH support.
• Estradiol elevation: Manage through TRT aromatase inhibitor protocol, not by reducing gonadorelin.
• Headaches or nasal congestion (if intranasal route used): Switch to subcutaneous.

Evidence reality check

Gonadorelin's mechanism is well-established — it is bioidentical GnRH and the diagnostic GnRH stimulation test has been used in endocrinology for decades. However, its specific use for fertility preservation during TRT is supported primarily by mechanistic reasoning and practitioner experience, not dedicated RCTs comparing gonadorelin to hCG or placebo in this context. The biological logic is sound, but high-quality comparative outcome data (pregnancy rates, semen parameters) specifically for the TRT-adjunct use case is limited.